• News On Bispecific Antibodies

    M802 bispecific antibody binds to a tumor target and an immune target simultaneously to recognize and link cancer cells and immune cells, subsequently forms an effective tumor-immune cell complex in c

    2017/12/21 52

  • First CAR-T approved on market: Novartis Priced Kymriah $475,000

    August 31, 2017, Novartis announced that the United States FDA has approved its CAR-T therapy Tisagenlecleucel (formerly known as CTL019) listed for the treatment of B cell precursor acute lymphoblast

    2017/10/27 13

Previous page1Next page Go to No.